Gastrointestinal Cancer

PV QA 1 - Poster Viewing Q&A 1

SU_9_2084 - Possibility of conversion surgery and histological evaluation in definite cT4 patients of esophageal cancer treated with preoperative chemoradiation followed by surgery

Sunday, October 21
1:15 PM - 2:45 PM
Location: Innovation Hub, Exhibit Hall 3

Possibility of conversion surgery and histological evaluation in definite cT4 patients of esophageal cancer treated with preoperative chemoradiation followed by surgery
M. Myojin1, M. Hosokawa2, Y. Dekura3, T. Takenouchi4, T. Ohuchi4, and H. Takahashi5; 1Keiyukaisapporo Hospital, Department of Radiation Oncology, Sapporo, Japan, 2Keiyukaisapporo Hospital, Department of Surgery, Sapporo, Japan, 3Department of Radiation Oncology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 4Keiyukaisapporo Hospital, Department of Pathology, Sapporo, Japan, 5Keiyukaidaini hospital, Department of Gasroenterology, Sapporo, Japan

Purpose/Objective(s): Patients of cT4NxM0 have been regarded as appropriate candidates for definitive chemoradiation (CRT) but as controversial for surgery following preoperative CRT. There is wide variation of mixed rate of cT3 in cT4 among institutions despite of best diagnostic technology. Objectives of this study are (1) to select definite cT4 (d-cT4) patients with consistent histological evidence and to compare d-cT4 with marginal cT3 from view of prognosis, (2) to discuss the possibility of conversion surgery in d-cT4 .

Materials/Methods: Marginally resectable 126 patients with cT3-4NxM0 were enrolled to preoperative CRT regimen. The regimen included cisplatin (70mg/m2 on day 1 and 28), 5-FU (700mg/m2 on days 1-5 and 28-32) and radiotherapy (RT, total 50.4Gy/28F). Within 6weeks after the accumulated RT dose reached 50.4Gy, the feasibility of esophagectomy was evaluated in all patients. Histological evidence of disappeared tumor by CRT are coagulation necrosis with/without replacement by fibrosis, xantho-granulomatous region with/without foreign body giant cells, and deposition of keratinized tissue without viable tumor cells. Three stages of surgical curability were defined as Cur A; sStage 0~lll, D>N and R0, as Cur B; neither Cur A nor C, and as Cur C; residual tumor and R2. Out of categorized 4 Grades (Gr 0 to 3) of histological effectiveness of CRT, no viable cancer cells were defined Gr 3. Conclusions were drawn from a retrospective analysis of phase II study for including marginal cT3 and cT4.

Results: The reasons which esophagectomy was not feasible were CR evaluation after CRT in 9 patients, PD after CRT in 6, and toxicities of CRT in 3. After all, 108 patients (average 64 years old, 43-80) were treated with CRT followed by surgery. By final examination of the differences between pretreatment T stages and pathological findings of surgical specimens, d-cT4 were 40 (37%) patients (between 11 of cT4a and 29 of cT4b, there was no statistical difference of survivals). As other 68 operated patients were not verified as d-cT4, they were defined as “cT3/<4” in this study. R0 surgery were done in 93 (86%) patients. In d-cT4, 22 (55%) were evaluated in Cur A, and 9 (22.5%) in Cur C, on the other hand in cT3/<4, 60 (88%) in Cur A and 1 (1.5%) in Cur C, respectively. Gr 3 histological effectiveness was presented in 11 (28%) patients of d-cT4, and 30 (44%) in cT3/<4. In univariate analyses for OS, age younger than 75, R0 and Gr 3 were not significant (p=0.92, p=0.24, p=0.16, respectively), and Cur A and cT3/<4 were significant (p=0.002, p<0.001, respectively). In a multivariate analysis for OS, only cT3/<4 alone was significant ( Exp.β 3.0, 95%CI 1.22-7.30, p=0.17). In 40 patients of d-cT4, 2 and 4-year survival rates were 56% and 42%, respectively.

Conclusion: Although we presented possibility of conversion surgery for definite cT4 and a fair evaluation of preoperative CRT, more effective multimodality therapy is expected because of the significant prognostic impact of depth of tumor invasion.

Author Disclosure: M. Myojin: None. M. Hosokawa: None. T. Takenouchi: None. H. Takahashi: None.

Miyako Myojin, MD, PhD

Biography:
Miyako Myojin M.D., PhD

I graduated Hokkaido University School of Medicine in Sapporo. I got PhD degree in Tohoku University by the investigation of antitumor effect induced by very low-dose TBI.
After 14 years clinical experience in Hokkaido Cancer Center, now I am working for Keiyukai Sapporo Hospital Dept. of Radiation Oncology as a chief radiation oncologist. My speciality is CRT/ RT for esophagel cancer and head & neck cancer.

Presentation(s):

Send Email for Miyako Myojin


Assets

SU_9_2084 - Possibility of conversion surgery and histological evaluation in definite cT4 patients of esophageal cancer treated with preoperative chemoradiation followed by surgery



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Possibility of conversion surgery and histological evaluation in definite cT4 patients of esophageal cancer treated with preoperative chemoradiation followed by surgery